Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
About this episode
Alan Bash discusses the commercialization of Carvykti, a leading CAR T therapy for multiple myeloma, and shares insights from his experience in the biotech industry.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ...
More episodes of Business Of Biotech
- Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
- The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
- Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
- Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
- Investing In Early-Stage Oncology With Yosemite's Dan McHugh
- Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.